Estrogen receptor α and β polymorphisms: Is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?

Menopause

Volumn 13, Issue 3, 2006, Pages 451-461

  Silvestri, Sandra ^a   Thomsen, Anne Bloch ^b   Gozzini, Alessia ^a   Bagger, Yu ^b   Christiansen, Claus ^b   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone mineral density; Cholesterol; Estrogen receptor

Indexed keywords

CHOLESTEROL; CYPROTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLITROPIN; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FOREARM; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; SPINE FRACTURE;

BONE DENSITY; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DENMARK; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOREARM; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 33745264409     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000182804.14385.a2     Document Type: Article

References (61)

1. Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003;73:15-20.
2. Thomsen AB, Silvestri S, Haarbo J, Christiansen C, Bjarnason NH. Associated response in bone and lipids during hormone replacement therapy. Maturitas 2004;47:39-45.
3. Shin A, Kang D, Nishio H et al. Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2003;80:127-131.
4. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-670.
5. Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res 1989;49:145-148.
6. Yaffe K, Lui LY, Grady D, Stone K, Morin P. Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. Biol Psychiatry 2002;51:677-682.
7. Shearman AM, Cupples LA, Demissie S, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003;290:2263-2270.
8. Lehtimaki T, Laaksonen R, Mattila KM, et al. Oestrogen receptor gene variation is a determinant of coronary reactivity in healthy young men. Eur J Clin Invest 2002;32:400-404.
9. Schuit SCE, Oei SH, Witteman JCM, et al. Estrogen receptor alfa gene polymorphisms and risk of myocardial infarction. JAMA 2004;291:2969-2977.
10. Gennari L, Becherini LML, Mansani R, et al. Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 2004;83:939-944.
11. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF. A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. J Bone Miner Res 2000;15:2222-2230.
12. Willing M, Sowers M, Aron D, et al. Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res 1998;13:695-705.
13. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 1996;11:306-311.
14. Bagger YZ, Jorgensen HL, Heegaard AM, Bayer L, Hansen L, Hassager C. No major effect of estrogen receptor gene polymorphisms on bone mineral density or bone loss in postmenopausal Danish women. Bone 2000;26:111-116.
15. Albagha OME, McGuigan FEA, Reid DM, Ralston SH. Estrogen receptor alfa gene polymorphisms and bone mineral density: haplotype analysis in women from the United Kingdom. J Bone Miner Res 2001;16:128-134.
16. Kobayashi N, Fujino T, Shirogane T, et al. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 2002;41:193-201.
17. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S et al. Estrogen receptor gene polymorphism is associated with bone mineral density in premenopausal women but not in postmenopausal women. J Endocrinol Invest 1998;21:487-493.
18. Kurabayashi T, Matsushita H, Tomita M, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effects of long-term hormone replacement therapy on bone mineral density. J Bone Miner Metab 2004;22:241-247.
19. Nordstrom P, Glader CA, Dahlen G, et al. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 2003;254:140-146.
20. Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN. Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int 2004;74:501-508.
21. Shearman AM, Karasik D, Gruenthal KM, et al. Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 2004;19:773-781.
22. Lau HHL, Ho AYY, Luk KDK, Kung AWC. Estrogen receptor beta gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 2002;31:276-281.
23. Khosla S, Riggs BL, Atkinson EJ, et al. Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. J Clin Endocrinol Metab 2004;89:1808-1816.
24. Rosenkrantz K, Hinney A, Ziegler A, et al. Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J Clin Endocrinol Metab 1998;83:4524-4527.
25. Sundarrajan C, Liao WX, Roy AC, Ng SC. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001;86:135-139.
26. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-735.
27. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-279.
28. Riis BJ, Johansen J, Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas 1988;10:51-58.
29. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61-65.
30. Marslev U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992;79:202-210.
31. Bjarnason NH, Byrjalsen I, Hassager C, Haarbo J, Christiansen C. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am J Obstet Gynecol 2000;183:550-560.
32. Alexandersen PA, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. Br J Obstet Gynecol 2000;107:356-364.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-densitylipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
34. Becherini L, Gennari L, Masi L, et al. Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet 2000;9:2043-2050.
35. Bagger YZ, Hassager C, Heegaard AM, Christiansen C. Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins. Climacteric 2000;3:84-91.
36. Ioannidis JPA, Stavrou I, Trikalinos TA, et al. Association of polymorphisms of the estrogen receptor alfa gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res 2002;17:2048-2060.
37. Weel AEAM, Uitterlinden AG, Westendorp ICD, et al. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999;84:3146-3150.
38. Brown MA, Haughton MA, Grant SFA, Gunnell AS, Henderson NK, Eisman JA. Genetic control of bone density and turnover: role of the Collagen lalfal, estrogen receptor, and vitamin D receptor genes. J Bone Miner Res 2001;16:758-764.
39. Vandevyver C, Vanhoof J, Declerck K, et al. Lack of association between estrogen receptor genotypes and bone mineral density, fracture history, or muscle strength in elderly women. J Bone Miner Res 1999;14:1576-1582.
40. Kurabayashi T, Matsushita H, Kato N, et al. Effect of vitamin D receptor and estrogen receptor gene polymorphism on the relationship between dietary calcium and bone mineral density in Japanese women. J Bone Miner Metab 2004;22:139-147.
41. Lau EM, Young RP, Lam V, Li M, Woo J. Estrogen receptor gene polymorphism and bone mineral density in postmenopausal Chinese women. Bone 2001;29:96-98.
42. Kim JG, Lim KS, Kim EK, Choi YM, Lee JY. Association of vitamin D receptor and estrogen receptor gene polymorphisms with bone mass in postmenopausal Korean women. Menopause 2001;8:222-228.
43. Ioannidis JP, Ralston SH, Bennett ST, et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004;292:2105-2114.
44. Milewicz A, Demissie M, Zatonska K, et al. Influence of dietary and genetic factors on metabolic status in obese and lean postmenopausal women. Gynecol Endocrinol 2003;17:333-338.
45. Lehrer S, Rabin J, Kalir T, Schachter BS. Estrogen receptor variant and hypertension in women. Hypertension 1993;21:439-441.
46. Matsubara Y, Murata M, Kawano K, et al. Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol 1997;17:3006-3012.
47. Lu H, Higashikata T, Inazu A, et al. Association of estrogen receptor alpha gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002;22:817-823.
48. Salmen T, Heikkinene AM, Mahonen A, et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res 2000;15:315-321.
49. Salmen T, Heikkinene AM, Mahonen A, et al. The protective effect of hormone replacement therapy on fracture risk is modulated by estrogen receptor alfa genotype in early postmenopausal women. J Bone Miner Res 2000;15:2479-2486.
50. Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P, et al. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol (Oxf) 2000;52:581-585.
51. Giguére Y, Dodin S, Blanchet C, Morgan K, Rousseau F. The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J Bone Miner Res 2000;15:1076-1084.
52. Kurabayashi T, Tomita M, Matsushita H, et al. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol 1999;180:1115-1120.
53. Han KO, Moon IG, Kang YS, Chung HY, Min HK, Han IK. Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab 1997;82:991-995.
54. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circ 2002;105:1879-1882.
55. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-974.
56. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
57. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor {beta}-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-4265.
58. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2004;24:145-155.
59. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-5578.
60. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ER-beta -/- mice. J Clin Invest 1999;104:895-901.
61. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ER-alpha-selective ligand. Endocrinology 2002;143:4172-4177.